Welcome to our 2024 Annual Review
Chairman’s message
Future digital solutions and clinical expertise in our specialized areas will bring us closer than ever to medical professionals, allowing us to improve patient care.Marc Rubiralta Chairman

CEO interview
We exceeded our sales budget across all geographies, regions, and most of our business units. Diagnostics sales grew by 6% at constant exchange rate and constant perimeter compared to 2023. And we also increased our operating income.Carlos Pascual CEO

Werfen in brief
We recorded a +6% increase in revenues, and improved operating income for 2024. With strong performances across all of our geographies and most of our business units, including Hemostasis and Acute Care, we launched groundbreaking new products, invested in our technology centers and continued to invest heavily in R&D.
Business highlights in 2024
Market position worldwide
Our leading positions are backed by the quality of our solutions, our innovation capabilities and heavy investment in R&D.
Note: All sales growth numbers are at Constant Exchange Rate and Constant Perimeter.